Turning Point Therapeutics, Inc. (TPTX)
Stock Price:
$104.42 USD
4.34 (4.34%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $106.00 +1.58 (1.51%) Oct 28, 4:47 PM
Key Info
| Market Cap |
4.40B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-133.65M |
| Shares Out |
42.17M |
| EPS (ttm) |
-3.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$104.42 |
| Previous Close |
$100.08 |
| Change ($) |
4.34 |
| Change (%) |
4.34% |
| Day's Open |
100.08 |
| Day's Range |
98.00 - 106.90 |
| Day's Volume |
965,089 |
| 52-Week Range |
31.30 - 122.85 |
More Stats
| Market Cap |
4.40B |
| Enterprise Value |
3.70B |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
42.17M |
| Float |
36.19M |
| EPS (basic) |
-3.59 |
| EPS (diluted) |
-3.74 |
| FCF / Share |
-2.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.76M |
| Short Ratio |
7.14 |
| Short % of Float |
10.38% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.04 |
| Revenue |
n/a |
| Operating Income |
-140.56M |
| Net Income |
-133.65M |
| Free Cash Flow |
-84.05M |
| Net Cash |
705.97M |
| Net Cash / Share |
16.74 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-13.73% |
| ROE |
-27.88% |
| ROIC |
-43.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$117.44*
(12.47% upside)
Low
77.0
Current: $104.42
High
134.0
Target: 117.44
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -77.72 | -25.64 | -16.73 |
| Net Income | -72.13 | -24.79 | -16.59 |
| Shares Outstanding | 24.12 | 3.39 | 3.34 |
| Earnings Per Share | -2.99 | -7.31 | -4.97 |
| Operating Cash Flow | -57.76 | -23.53 | -12.64 |
| Capital Expenditures | -1.74 | -0.30 | -0.09 |
| Free Cash Flow | -59.50 | -23.84 | -12.73 |
| Cash & Equivalents | 409 | 101 | 45.03 |
| Total Debt | 5.06 | - | - |
| Net Cash / Debt | 404 | 101 | 45.03 |
| Assets | 422 | 103 | 45.91 |
| Liabilities | 17.85 | 152 | 70.75 |
| Book Value | 404 | -48.41 | -24.84 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Turning Point Therapeutics, Inc. |
| Country |
United States |
| Employees |
109 |
| CEO |
Athena Countouriotis |
Stock Information
| Ticker Symbol |
TPTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TPTX |
| IPO Date |
April 17, 2019 |
Description
Turning Point Therapeutics, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.